- Khiron's medical cannabis products to be carried at Locatel's
large-format pharmacy locations in Colombia
- Locatel is an important pharmacy, healthcare products and
medical equipment retailer in Colombia with a database of 2 million patients
and customers, and experience managing magistral preparations
- Locatel e-commerce channels enable product deliveries to all
markets and territories across Colombia
- Locatel's operations deemed an essential service in
Colombia during COVID-19 pandemic,
ensuring continued access to filling and delivery of
prescriptions
TORONTO, April 22, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, announces that it has entered into a
sales and distribution agreement with Locatel, a pharmacy,
healthcare products, and medical equipment retailer with a database
of over 2 million patients in Colombia. The agreement immediately brings
Khiron's medical cannabis products to Locatel's pharmacies and
medical equipment stores in Bogota
and Cartagena.
"Khiron is the only company to have all necessary permits and
certificates to sell medical cannabis in Colombia, and now the focus is on service and
solving patient needs for the last mile," comments Alvaro Torres, Khiron CEO and director. "The
Locatel brand is highly respected among Colombians and the
company's philosophy aligns with our own. We look forward to
partnering with Locatel to improve access to medical cannabis for
patients throughout the country."
Effective immediately Khiron's low-THC, CBD-rich magistral
preparations will be available through Locatel stores across
Colombia's largest urban centres,
including in Bogota, with a
population of 10 million, and Cartagena, with a population of 1
million.
"This has always been about providing people with medicine they
vitally need, and it must be available with home delivery, and for
pick up at trusted locations such as Locatel," Torres
continued.
"With our large customer network, customer database, and
commitment to patient health, working with Khiron is a clear
strategic opportunity for both organizations. Like us, Khiron is
focused on patient care and we commend them for achieving this
milestone to bring medical cannabis to Colombia," comments Eurice Troya, CEO Locatel Colombia.
About Locatel
With an integrated health concept,
Locatel offers products, services, events and educational programs
that help customers maintain or recover their quality of life. The
company operates health markets in Colombia, Venezuela and the US, and prides itself on
exemplary customer service and resources delivering better patient
care. Please visit: https://www.locatelcolombia.com/
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is the dominant integrated medical cannabis company in
Latin America. Khiron has core
operations in Latin America, along
with activity in North America and
Europe, and is licensed in
Colombia for the cultivation,
production, domestic distribution, and international export of both
tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.
The Company delivers best in class regulatory compliance, has the
first approved line of CBD cosmetic products on shelf
in Colombia, and is fully authorized to manufacture high- and
low-THC medical cannabis, and to fill prescriptions for low-THC
medical cannabis in the country.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities
in the United States. The securities have not been and
will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state
securities laws and may not be offered or sold within the
United States or to U.S. Persons
(as such term is defined in Regulation S under the U.S. Securities
Act) unless registered under the U.S. Securities Act and applicable
state securities laws or an exemption from such registration is
available
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-signs-medical-cannabis-distribution-deal-in-colombia-with-locatel-301044918.html
SOURCE Khiron Life Sciences Corp.